Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21384816 | 0.98 | MEN1 (0.64) | MEN1CYP2D6KMT2AHSD11B1MGLL | |
| SCHEMBL4023293 | 0.88 | HSD11B1 (0.63) | HSD11B1MGLLKDM2BCES2CES1 | |
| SCHEMBL18624032 | 0.87 | MEN1 (0.62) | MEN1CYP2D6KMT2AHSD11B1MGLL | |
| Tert-Butyl Formate SCHEMBL27968807 | 0.87 | MEN1 (0.51) | MEN1CYP2D6KMT2AHSD11B1MGLL | |
| SCHEMBL1855141 | 0.84 | HSD11B1 (0.60) | MEN1KMT2AHSD11B1MGLLKDM2B | |
| SCHEMBL19650840 | 0.84 | HSD11B1 (0.60) | MEN1KMT2AHSD11B1MGLLKDM2B | |
| SCHEMBL1583171 | 0.83 | MEN1 (0.66) | MEN1CYP2D6KMT2A | |
| SCHEMBL26081057 | 0.83 | HSD11B1 (0.58) | MEN1KMT2AHSD11B1MGLLKDM2B | |
| SCHEMBL7418491 | 0.83 | HSD11B1 (0.56) | MEN1CYP2D6KMT2AHSD11B1MGLL | |
| Hydrochloric Acid SCHEMBL11616870 | 0.82 | MEN1 (0.69) | MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8974806-B2 | Method for producing aqueous active substance compositions of active substances that are hardly soluble in water | BASF AKTIENGESELLSCHAFT (DE) | 2015-03-10 | — | — | US | disclosed |
| US-8974806-B2 | Method for producing aqueous active substance compositions of active substances that are hardly soluble in water | BASF AKTIENGESELLSCHAFT (DE) | 2015-03-10 | — | — | US | disclosed |
| EP-1973401-B1 | SOLVENT MIXTURE FOR PREPARING WATER-DILUTABLE LIQUID CONCENTRATE FORMULATION OF ORGANIC PESTICIDE COMPOUNDS | BASF SE (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-8741324-B2 | Liquid pesticide compositions | BASF SE (DE) | 2014-06-03 | — | — | US | disclosed |
| EP-1763300-B1 | USE OF ETHER GROUP-CONTAINING POLYMERS AS SOLUBILIZERS | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2514311-A1 | Method for protecting against phytopathogens with kiralaxyl, usage and means for same | ISAGRO S.p.A. (IT) | 2012-10-24 | — | — | EP | disclosed |
| EP-2514310-A1 | Method for protecting against phytopathogens with kiralaxyl, usage and means for same | ISAGRO S.p.A. (IT) | 2012-10-24 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1572668-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004060865-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MEN1 3295/4885CYP2D6 728/4885KMT2A 4267/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | MEN1 4855/4885CYP2D6 3964/4885KMT2A 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.